GUARDIAN the world's first and only heart attack warning system

Benefits of the GUARDIAN's real-time alerts

The Guardian | Hydrix

Despite education and public healthcare campaigns patients still delay going to the hospital when they experience symptoms of a possible heart attack. The GUARDIAN monitors a patient’s heart 24/7 and alerts the patient upon detection of signals related to acute coronary syndrome (ACS) events alerting the patient to seek medical care without delay. By getting to the hospital quickly the patient is likely to have better outcomes.

ALERTS1,2 GUARDIAN pivotal randomised study for safety and efficacy of the GUARDIAN and highlighted a broad range of benefits to patients, clinicians and the healthcare system.

The GUARDIAN reduces time to door

90% of MI patients presented symptom to door under 2 hours. The overall reduction in symptom to door time was reduced from a median of 8 hours to 1.7 hours in the treatment group.

With STEMI and NSTEMI patients – a reduction was seen from a median of 12.7 hours to 1.6 hours2.

The GUARDIAN detected 42 silent ACS events in the study, that is an ASC event where the patient did not experience any symptoms. These patients arrived to door in a medium time of 1.4 hours, prompting early myocardial saving treatment.

The Guardian | Hydrix

The GUARDIAN reduces myocardial damage

After an alert and once the patient reaches the Emergency Department accepted international cardiac clinical pathways are implemented. The GUARDIAN reduces delays to treatment to improve outcomes for patients. In the ALERTS study GUARDIAN patients that had an occlusive event were less likely to have new onset LV dysfunction at discharge (35% v 4%).

The Guardian, Myocardial | Hydrix

Detects other co-morbidities

During the ALERTS study, the GUARDIAN revealed a need for a therapeutic device in 5% of study patients with an overall detection of new serious medical conditions in 8.68% of the study population1.

In addition to the EMERGENCY alarm, the GUARDIAN also has a SEE DOCTOR alert which indicates a detection of cardiac activity that should be evaluated by a medical professional.

The Guardian | Hydrix

Reduces impact on hospital resources

In the ALERTS study, it was demonstrated that the GUARDIAN prompted patients to seek medical attention for asymptomatic ACS events. There was a 26% reduction in the False Positive Rate and unnecessary tests compared to patient symptoms as a trigger for ED visits.


1. Gibson, M., Holmes, D., Mikdadi, G., et al. Implantable Cardiac Alert System for Early Recognition of ST-Segment Elevation Myocardial Infarction. JACC. 2019; 73(15):1919-1927.

2. Holmes, D.R., Krucoff, M.W., Mullin, C., et al. Implanted Monitor Alerting to Reduce Treatment Delay in Patients with Acute Coronary Syndrome Events. JACC. 2019; 74(16):2047-2055.

The GUARDIAN is not available for supply in Australia and is currently not included on the Australian Register of Therapeutic Goods.